• The first quarter of fiscal 2026 was an important milestone for the company, as it represents the first full reporting period that FWDI operates as the worlds largest Solana (SOL) treasury company.
• The company announced information about treasury holdings, staking performance, financial results, and more.
• FWDI also mentioned several milestones and accomplishments the company has reached, and the goals for the future.

Forward Industries (NASDAQ: FWDI), a SOL treasury company, recently reported the company’s fiscal first quarter 2026 financial and operating results

The first quarter of fiscal 2026 is the company’s first full reporting period as the world’s largest Solana treasury company, and it moved from simply launching the strategy, to actively executing it through market volatility.

As of December 31st, 2025, the company has liquid SOL holdings of 6,962,501 SOL. Since the inception of the strategy, FWDI’s validator infrastructure has generated between 6.5% and 7.2% gross annual percentage yield (“APY”) before fees, which already outperforms many peer validators.

Also as of the end of 2025, the company has generated more than 112,171 SOL in staking rewards, and almost all of FWDI’s SOL holdings are currently staked. The company also had $25.4 million in cash at the end of 2025, and no institutional debt.

The announcement indicated that the company’s revenue for the first quarter of fiscal 2026 increased by more than 4X, going from $4.6 million in the prior-year period, up to $21.4 million. This growth was largely driven by staking revenue that the company generated through the Solana treasury strategy.

Operationally, the company also made steady progress, as it expanded how FWDI participates on the Solana blockchain. First, it launched fwdSOL, the company’s proprietary liquid staking token, which lets FWDI earn native staking yield, while maintaining liquidity and deploying capital across the Solana ecosystem.

The company also began testing a proprietary automated market maker, developed alongside Galaxy, which positions the company to participate directly in on-chain trading activity. These moves highlight the company’s focus on building an operating platform that’s active, scalable, and designed to enhance SOL-per-share over time.

Finally, as Solana continues to be adopted as real financial infrastructure, the company believes FWDI is well-positioned to evolve from a treasury to an active and value-generating business that’s aligned with the growth of the network.

About Forward Industries Inc. (NASDAQ: FWDI)

Forward Industries is building and managing a large-scale Solana (SOL) treasury, and is backed by many of the most influential investors in the digital space. It has acquired more than 6.9 million SOL, and the company’s strategy involves creating value by actively participating in the Solana ecosystem via on-chain opportunities like staking, lending, and engaging in decentralized finance (“DeFi”).

For more information, visit the company’s website at www.ForwardIndustries.com.

NOTE TO INVESTORS: The latest news and updates relating to FWDI are available in the company’s newsroom at https://ibn.fm/FWDI

Disseminated on behalf of Nevada Organic Phosphate Inc. (CSE: NOP) (OTCQB: NOPFF) and may include paid advertising.

• Early drilling at Murdock Mountain project in Nevada shows an average grade of 10.93% P₂O₅ in the Upper Phosphatic Zone, alongside calcium, magnesium, silicon, and trace micronutrients.
• Heavy metals such as cadmium, arsenic, and lead were reported well below common organic certification thresholds.
• Management says the chemistry supports slow-release phosphorus and soil conditioning benefits.
• The company is positioning Murdock Mountain as a potential direct-ship organic phosphate input rather than a conventional chemical fertilizer feedstock.
• Nevada Organic Phosphate aims to advance the project amid rising demand for domestic, low-contaminant fertilizer sources.

Nevada Organic Phosphate (CSE: NOP) (OTCQB: NOPFF), a B.C.-based leader in organic sedimentary phosphate exploration, announced that new assay interpretations from its Murdock Mountain property indicate the material could function as a naturally balanced, multi-nutrient mineral fertilizer aligned with organic and regenerative farming practices (https://ibn.fm/oTvGI).

In a February 10 update, the Vancouver-based explorer reported continued progress analyzing samples from the first six drill holes in the Upper Phosphatic Zone (“UPZ”). The company pointed out that weighted average grades of 10.93% P₂O₅ are now supported by broader geochemical data showing meaningful levels of calcium, magnesium, potassium, iron, manganese, silicon, and trace micronutrients.

Chief executive Robin Dow said the results suggest Murdock Mountain is shaping up as more than a single-nutrient phosphate deposit. “These assay results continue to validate the strategic importance of Murdock Mountain,” Dow said in the release. “We are defining a uniquely clean and naturally balanced phosphate system at a time when growers, distributors, and regulators are all demanding lower-risk nutrient sources. The chemistry we are seeing, with low impurities, meaningful co-nutrients, and slow-release phosphorus, aligns directly with the needs of organic and regenerative agriculture.”

The UPZ is located at Murdock Mountain in northeastern Nevada. Nevada Organic Phosphate is advancing the project as a potential direct-ship raw rock phosphate operation aimed at organic agriculture markets, rather than the conventional chemical fertilizer supply chain.

According to the company, ongoing analysis shows slow-release phosphorus combined with co-nutrients that support soil structure, microbial activity, and long-term fertility; attributes increasingly sought by organic and regenerative growers.

In the update, management highlighted what it described as an “exceptionally clean” impurity profile. Cadmium, arsenic, lead, chromium, and mercury were reported at levels well below typical regulatory limits used by organic certifiers in North America. The company also noted low radionuclide readings, which can be a concern for sedimentary phosphate deposits globally.

Director Garry Smith, P.Geo., said the low contaminant levels reduce certification risk for organic producers and may offer a regulatory advantage as limits tighten in key agricultural markets. “As global contaminant limits tighten, clean phosphate sources are becoming increasingly scarce,” said Smith. “NOP’s low cadmium, low arsenic, and low radionuclide signature reduces regulatory friction for growers and positions the company to compete in premium fertilizer markets where compliance and purity matter.”

The company believes this clean profile differentiates its Nevada material from many commercial phosphate sources that require blending or processing to meet organic standards.

Beyond phosphorus, Nevada Organic Phosphate emphasized the agronomic role of naturally occurring calcium, reported at roughly 29% CaO, as well as magnesium, silicon, zinc, manganese, molybdenum, sulfur, and iron. These elements, management said, appear at concentrations sufficient to provide measurable soil and crop benefits.

While the company does not plan to market the product as a liming agent, it noted that the calcium content could help moderate soil acidity and improve nutrient availability, offering what it called an incidental agronomic benefit for growers.

The UPZ also showed relatively low uranium compared with many sedimentary phosphate deposits worldwide, according to internal benchmarking against U.S., South American, and European data sets referenced in the release.

According to Nevada Organic Phosphate , the Murdock Mountain property is one of the only large-scale organic sedimentary phosphate projects in North America, hosting a phosphate bed extending approximately 6.6 kilometres, with additional applications that could expand the prospective strike length beyond 30 kilometres. The project is located near highway and rail infrastructure linking northeastern Nevada with California, which the company views as advantageous for future logistics.

The company is targeting demand driven by organic food production and regenerative farming practices, as U.S. agriculture is gradually shifting away from highly soluble chemical phosphates toward reactive, naturally occurring mineral inputs that support soil biology.

That shift comes as fertilizer supply chains remain under scrutiny and governments encourage domestic sourcing of critical agricultural inputs. Murdock Mountain can potentially serve as a premium input for growers seeking clean phosphorus combined with secondary nutrients, rather than a bulk commodity feedstock for industrial fertilizer processing.

The current results are based on weighted averages from UPZ intercepts in the first six drill holes, with additional soil and geological work ongoing. Management said future steps will focus on refining target zones and advancing the project toward resource definition, subject to permitting and financing.

“The Upper Phosphatic Zone is demonstrating a remarkably consistent geochemical signature across the first six drill holes,” added Smith. “Calcium, magnesium, silicon, iron, zinc, manganese, and molybdenum all occur at agronomically relevant levels, and the impurity profile remains exceptionally low. This is not a single-nutrient ore body – it is a multi-nutrient mineral input with a clean chemistry advantage that is increasingly rare in global phosphate deposits.”

For more information, visit the company’s website at www.NevadaPhosphate.com.

NOTE TO INVESTORS: The latest news and updates relating to NOP are available in the company’s newsroom at https://ibn.fm/NOP

• The broader wearable technology market has been expanding rapidly as connectivity, health monitoring and intuitive user interfaces drive consumer and enterprise interest
• The company’s vision also anticipates broader adoption beyond gaming, healthcare or fitness applications

The global appetite for more intuitive, seamless interaction with technology is accelerating, and AI-powered, touchless sensing wearables are emerging as a cornerstone of this transformation. Wearable Devices (NASDAQ: WLDS) is at the forefront of this trend, leveraging neural-input interfaces and gesture recognition technology to provide hands-free control solutions that may redefine how users interact with consumer electronics and smart environments. Recent developments from the company highlight both growing market demand and Wearable Devices’ strategic role in unlocking new use cases for touchless wearable technology.

The global wearable technology market is experiencing rapid growth, driven by advances in connectivity, health monitoring, and intuitive user interfaces. According to Research and Markets, the market is expected to expand from approximately $82.33 billion in 2024 to more than $230 billion by 2033, reflecting a compound annual growth rate of about 12.1% as demand rises for AI-enabled wearables with advanced sensors and interaction capabilities.

Gesture recognition and touchless sensing are emerging as critical enablers of next-generation human-machine interaction. Grand View Research estimates the gesture recognition market will grow from roughly $25.44 billion in 2024 to over $70.18 billion by 2030, representing an 18% CAGR. The broader gesture recognition and touchless sensing market is forecast to expand from $28.4 billion in 2025 to nearly $125.9 billion by 2032, driven by adoption across consumer electronics, automotive, and enterprise applications.

This trend is further reinforced by the rapid expansion of extended reality glasses as a core wearable category. According to a December 2025 report by International Data Corporation titled “Global XR Shipments Rebound Behind Glasses-First Momentum, IDC Reports,” global XR glasses shipments are forecast to grow approximately 320% in 2025, reaching 10.6 million units. Growing mainstream acceptance of XR glasses, alongside continued enthusiasm from gamers for mixed reality and large-format experiences, is expected to drive cumulative shipments of approximately 105.7 million devices from 2025 through 2029, with annual shipments reaching about 29.7 million units by 2029 and a projected compound annual growth rate of 29.3%.

At the intersection of these trends stands Wearable Devices, a company dedicated to advancing touchless interaction through neural input interfaces that translate subtle finger movements and hand gestures into device control. The company’s technology centers on a novel approach that enables users to manipulate a wide variety of digital devices, from consumer electronics and smartwatches to augmented and virtual reality headsets, drones and robots, without physically touching a screen or controller. The company’s focus reflects a shift beyond conventional touch or voice input toward a more intuitive, gesture-driven experience, a direction underscored by the broader market’s evolution toward AI integration and natural user interfaces.

The company’s Mudra Link and Mudra Band products illustrate their early traction in both the consumer and enterprise segments. In the first half of 2025, Wearable Devices began recognizing revenue from the Mudra Link, a universal gesture control wearable wristband compatible with both Android and iOS devices, while also continuing to generate revenue from the Mudra Band for Apple Watch. These products expand the company’s reach while demonstrating the practical application of its core technology in real-world use cases.

AI-enabled wearable devices themselves are experiencing rapid growth. A report by the Brainy Insights projects that the global wearable AI market, which includes devices with built-in artificial intelligence capabilities, could expand from approximately $27.06 billion in 2023 to around $289.38 billion by 2033, propelled by consumer demand for advanced functionality such as personalized data insights, on-body intelligence and seamless integration with digital ecosystems. In this context, Wearable Devices focuses on AI-driven gesture recognition and neural input control positions the company to potentially capture a share of a segment that converges sensor innovation with intuitive interaction paradigms. Recent industry developments, including Apple’s acquisition of Q.ai, underscore the growing emphasis on advanced input and interaction technologies. As AI becomes more pervasive in wearables, differentiation is increasingly expected to hinge on intuitive, touchless methods of capturing user intent.

The company’s vision also anticipates broader adoption beyond gaming, healthcare or fitness applications. Gesture-based control and neural interfaces may find applicability in augmented reality glasses, virtual reality platforms, industrial IoT systems and connected environments where hands-free interaction is desirable for safety, convenience or accessibility. As demand for AI-powered, intuitive wearables continues to expand across these diverse sectors, Wearable Devices’ technology could become a foundational component of future user-centric design, particularly as developers and manufacturers seek ways to embed smarter, more responsive interfaces into next-generation devices.

The market for AI-powered, touchless sensing wearables is growing quickly and drawing stronger interest from both consumers and industry, backed by strong projected growth rates across the wearable, gesture recognition and touchless sensing segments. Wearable Devices’ work in neural input interfaces and gesture control technology reflects a broader movement toward more natural human-machine interaction, and its expanding product suite illustrates how companies in this space are responding to evolving demand. With a marketplace that values seamless, intuitive control and advanced AI integration, Wearable Devices is positioning itself to benefit from the wave of innovation sweeping through the wearable technology landscape.

For more information, visit www.WearableDevices.co.il.

NOTE TO INVESTORS: The latest news and updates relating to WLDS are available in the company’s newsroom at https://ibn.fm/WLDS

Disseminated on behalf of LaFleur Minerals Inc. (CSE: LFLR) (OTCQB: LFLRF) (FSE: 3WK0) and may include paid advertising.

• LaFleur Minerals anticipates the imminent completion of its Preliminary Economic Assessment (“PEA”) to guide its pending gold production at a sprawling site in the renowned Abitibi Greenstone Belt of Eastern Canada
• LaFleur is completing upgrades and refurbishments to get its Beacon Gold Mill operating in the next quarter with feedstock from its nearby Swanson Gold Deposit and potentially other area miners
• The company has 445 mineral claims and one mining lease at the Swanson Gold Project spanning more than 18,000 hectares (about 44,500 acres), hosting multiple gold targets, primarily the key Swanson Gold Deposit
• Company CEO Paul Ténière recently participated in a webinar that addressed the company’s assets, the company’s progress toward production, and its strategic aims

Gold explorer and near-term gold producer LaFleur Minerals (CSE: LFLR) (OTCQB: LFLRF) is preparing the restart of gold production at its Beacon Gold Mill as a processing outlet for company feedstock sourced from its nearby Swanson Gold Deposit in the celebrated Abitibi Gold Belt of Eastern Canada, where more than 300 million ounces of gold have been produced historically or accounted for with current reserve estimates (https://ibn.fm/RZlLz).

“(The mill) has a name plate of 750 (tonnes per day of production capacity), but we are looking at upgrades and refinements to get that to at least 1,000 tonnes or more per day,” LaFleur CEO Paul Ténière said during a Feb. 10 webinar broadcast by Red Cloud Securities (https://ibn.fm/t5FLD). “It is able to process gold, silver, and even a little bit of base metals as well, so it can handle multi-element-type deposits. We’re fully permitted at the mill but also at the tailings storage facility for up to 1.8 million tonnes of tailings.”

LaFleur obtained the idled gold mill at a bargain price in bankruptcy proceedings a few years ago, and the mill has become a key asset thanks in part to its access to power structure and skilled labor in the heavily explored and prolific gold belt.

“The mill’s barely run since it was opened, so I would say there’s at least over 90% of capacity still left,” Ténière said. “And at the current rate that we’re looking at, we’re looking at about nine years of life for that tailings storage facility. So all of that has been kept up since we took over the asset.”

The company aims to run a 100,000-tonne bulk sample from the Swanson Gold Deposit and then build into a larger operation, and is awaiting a Preliminary Economic Assessment (“PEA”) that will provide further guidance on its plans.

“I was hoping that they (the PEA results) would be out by the time of having this discussion, but shortly they will be coming out and then we’ll be able to get a lot more detail into the economics and also the mine plan,” Ténière said.

Plans to add a dedicated rail spur through the Swanson Property and the Beacon Gold Mill site to facilitate efficient loading and transport of material would provide the company with a significant economic benefit through reduced hauling costs, decreased pollutants and increased safety by reducing truck traffic through nearby villages if such an agreement with government and railway officials can be successfully reached.

LaFleur has built its available capital through $7.8 million in financing to restart gold production at the mill (https://ibn.fm/YhlEG), which comes at a strategic inflection point as the company shifts from being primarily an explorer toward gold production and revenue generation. This transition is typically one of the hardest and most capital-intensive phases for a junior mining company and having secured sufficient funding at this moment is crucial for moving from planning into actual operations, and it seems that LaFleur has done this seamlessly. The LIFE and flow-through offerings were upsized and oversubscribed showing strong investor interest and confidence in LaFleur’s plans and assets, and funds the restart of a fully permitted mill and materially reduces execution risk at a pivotal stage in its development.

“Primarily we’re looking at Beacon to process ore from our own deposits, and we’re also looking to generate cash as quickly as possible after we’ve completed the upgrades and refurbishments,” Ténière said. “Initially we’re looking a bulk sample of 100,000 tonnes — could get up to about 4,200 ounces of gold out of that, and could be even more depending on our cutoff. But we are looking to have that going fairly quickly. Because Swanson sits on a mining lease, there’s a lot less permitting required.”

For more information, visit the company’s website at LaFleurMinerals.com.

NOTE TO INVESTORS: The latest news and updates relating to LFLRF are available in the company’s newsroom at https://ibn.fm/LFLRF

Qualified Person Statement:

All scientific and technical information contained in this article has been reviewed and approved by Louis Martin, P.Geo. (OGQ), Exploration Manager and Technical Advisor of the company and considered a Qualified Person for the purposes of NI 43-101.

• WLDS recently announced a strategic partnership with Rokid to enable neural, touch-free control for AI and AR smart glasses
• Wearable Devices Ltd. Operates at the nexus of artificial intelligence, neural sensing, and intuitive human-computer interaction
• These updates highlight the company’s broader mission: to redefine the way users interact with AI-powered wearables via natural, frictionless neural input

Wearable Devices (NASDAQ: WLDS) continues to venture into new frontiers with its proprietary neural interface technology, strategically targeting the quickly evolving smart glass and augmented reality market. In a recent announcement, the company made public its collaboration with Rokid, a leading force in human-computer interaction and AR glasses, to deliver seamless, wrist-based gesture control for Rokid’s AI and AR eyewear (ibn.fm/2mobH).

Under the partnership, WLDS’s Mudra Link neural wristband can now work with Rokid Glasses, enabling pre-mapped gestures, out-of-the-box pairing, and a seamless onboarding experience. Both companies plan to implement a joint marketing approach, as well as a consumer bundle rollout, in the second quarter of 2026.

With AI-powered smart glasses gaining wider acceptance, input remains one of the difficulties faced by the category. Although software and hardware capabilities like navigation, real-time translation, and transcription have evolved quickly, intuitive control is still not catching up quickly enough. Wearable devices are trying to solve the challenge by transforming subtle neural signals from the wrist into reliable, touch-free commands, making it possible for users to interact naturally without using touchpads, external controllers, or voice prompts.

The company already carries a solid reputation as a force in the AI-enabled wearables sector through its Mudra Link and Mudra Band products. These products enable gesture-based interaction across a broad range of platforms such as smartwatches, smartphones, VR headsets, AR glasses and other Bluetooth-enabled devices. The partnership with Rokid underscores the scalability of Wearable Devices’ technology, placing it as a foundational input layer for the entire wearable solutions ecosystem.

This strategic direction is further validated by recent moves from leading global technology companies, including Apple’s acquisition of Q.ai for approximately $2 billion. The transaction highlights a growing industry focus on the interface and input layer as the next major battleground for AI-driven devices. As artificial intelligence becomes increasingly embedded in wearables, spatial computing platforms, and ambient systems, the ability to capture user intent through natural, frictionless input is emerging as a key differentiator. Apple’s investment in silent and micro-expression-based interaction reinforces the view that future AI value creation will extend beyond software models to the foundational technologies that enable intuitive, hands-free, and context-aware user interaction, directly aligning with the long-term direction of advanced wearable ecosystems.

Looking ahead to 2026, the company intends to build on this momentum and redefine the boundaries of human-machine interaction through its emerging AI initiatives. Beyond gesture recognition, the company is advancing its proprietary Large MUAP Model (“LMM”) and edge AI capabilities with the goal of supporting a new neural standard for the AI era. The company’s technology is designed to embrace the latest AI innovations, introducing” Vibe Coding” tools accessible to developers, alongside autonomous agent-based workflows utilized by the company to accelerate further development. By processing intent directly on the wrist, the company aims to ensure that as digital systems become smarter, user control remains seamless and intuitive.

These latest updates highlight Wearable Devices’ broader mission: to redefine human-computer interaction by making control intuitive, effortless and invisible. From neural interfaces that adapt to individual users to gesture based inputs for AI glasses, WLDS is creating the needed framework that makes it possible for intelligent devices to be used in everyday life.

For more information, visit www.WearableDevices.co.il.

NOTE TO INVESTORS: The latest news and updates relating to WLDS are available in the company’s newsroom at https://ibn.fm/WLDS

• LIXTE recently announced advances in its approach to cancer therapy through its proprietary compound LB-100
• Alongside clinical development news, LIXTE is sponsoring the Good Health: Mind, Body & Soul Summit
• These two announcements paint a picture of a company advancing on multiple fronts

LIXTE Biotechnology Holdings (NASDAQ: LIXT) is entering 2026 with momentum on both scientific and community fronts, announcing progress in its lead oncology program while also sponsoring a major health and wellness summit focused on addressing disparities in care. The company’s announcements highlight advances surrounding LB-100, its first-in-class cancer therapy candidate designed to enhance the effectiveness of existing treatments and underscore its involvement in community health initiatives through its sponsorship of the Good Health: Mind, Body & Soul Summit.

Last week, LIXTE outlined advances in its approach to cancer therapy through its proprietary compound LB-100, which works by inhibiting Protein Phosphatase 2a (“PP2A”), an enzyme involved in cell growth regulation, DNA repair and immune modulation. The company described this mechanism as a “novel approach to enhancing cancer therapy,” positioning LB-100 as a potential amplifier of existing chemotherapies and immunotherapies rather than a standalone agent.

The release explains that, by targeting PP2A, LB-100 may make tumor cells more susceptible to treatment, promoting stronger immune responses and enhancing the effects of existing therapies. This strategy reflects a broader trend in oncology to improve outcomes by augmenting established treatment regimens rather than relying solely on new cytotoxic agents. LB-100 has shown evidence of tolerability and anticancer activity in early clinical settings, and LIXTE continues to pursue clinical evaluation in multiple tumor types.

Clinical programs for LB-100 have drawn attention because they explore its use not only in combination with traditional chemotherapies but also alongside modern immunotherapies, which are transforming cancer care for many patients. The company’s emphasis on PP2A inhibition aligns with its broader oncology strategy, which has been documented in other industry and investor resources as a unique therapeutic approach within precision oncology.

Alongside clinical development news, LIXTE announced that it is sponsoring the Good Health: Mind, Body & Soul Summit, an invitation-only event scheduled for February 19 at Morehouse College in Atlanta. The summit, rooted in the legacy and music of hip-hop group De La Soul, is designed to explore health-equity issues impacting Black men and their families, bringing together leaders in health, culture, science and community to discuss a wide range of topics including cancer, heart disease, mental health and overall wellness.

According to the company, the summit aligns with LIXTE’s mission as a clinical-stage pharmaceutical company advancing cancer care through LB-100, as well as the work of its European subsidiary LIORA Technologies. The company’s sponsorship underlines its recognition that scientific progress must be paired with community engagement and awareness, particularly for populations that historically experience health disparities.

The Good Health summit will feature discussions on disease prevention, treatment access, mental well-being and generational health themes, aiming to foster a space where medical science and lived experience intersects. By participating in such initiatives, LIXTE is extending its influence beyond drug development into conversations about how healthcare systems and scientific innovation can better serve underrepresented communities. This integration of clinical ambition with social advocacy reflects a broader trend among biotechnology firms to address both scientific and societal dimensions of illness and treatment.

Taken together, these two announcements paint a picture of a company advancing on multiple fronts. On the scientific side, LIXTE’s work with LB-100 represents an innovative angle in oncology drug development, not by creating yet another cytotoxic agent but by enhancing the performance of existing therapies and potentially increasing their effectiveness. This approach may appeal to clinicians and researchers looking for ways to improve outcomes for patients with resistant or hard-to-treat cancers.

On the community engagement side, sponsoring the Good Health Summit positions LIXTE as an organization aware of the broader context in which cancer care and general health services are delivered. By aligning its corporate mission with an event focused on health equity, the company is helping draw attention to disparities that impact access, outcomes and public understanding of disease. This reflects an understanding within the broader pharmaceutical industry that scientific innovation and community engagement are mutually reinforcing aspects of long-term success.

Looking ahead, developments such as advances in LB-100’s clinical programs and participation in community health initiatives could help LIXTE shape its identity not just as a biotech developing a promising oncology compound but as a company engaged in the broader dialogue of health equity. For investors, clinicians and patients alike, these dual narratives of scientific progress and social engagement may help position LIXTE as a company aware of both the technical and human sides of modern healthcare.

For more information, visit the company website at https://lixte.com.

NOTE TO INVESTORS: The latest news and updates relating to LIXT are available in the company’s newsroom at ibn.fm/LIXT

• ETST operates as an active strategic holding company, acquiring and optimizing businesses through direct management and governance.
• The company’s core operations focus on the health and wellness sector via a vertically integrated portfolio.
• ETST’s mission centers on building durable shareholder value through regulatory discipline, operational control, and scalable growth platforms.

A Hands-On Approach to Portfolio Management

Earth Science Tech (OTC: ETST) is redefining the traditional holding company model by building a diversified portfolio designed for long-term sustainability. Unlike passive investment vehicles, ETST takes an active role in its subsidiaries, utilizing hands-on management and disciplined execution to enhance performance across the board.

Through its wholly owned subsidiaries, ETST operates a vertically integrated network that includes high-quality compounding pharmacies, telemedicine platforms, and specialized healthcare facilities. This “driver’s seat” approach allows the company to dictate strategy, streamline capital allocation, and ensure rigorous regulatory compliance-critical factors in today’s complex healthcare landscape.

Capitalizing on the Digital Healthcare Revolution

ETST’s primary operations are positioned at the intersection of telemedicine and pharmaceutical service sectors experiencing a surge in demand driven by digital transformation and an aging population.

As the global healthcare market shifts toward tech-powered, cost-efficient delivery, ETST’s telemedicine platforms are uniquely positioned to scale. By focusing on businesses that can navigate complex regulatory environments, the company ensures that its growth is not just rapid, but resilient.

Diversification and Operational Excellence

Beyond healthcare, ETST’s portfolio extends into strategic real estate and consumer-focused markets. This multi-faceted approach provides a dual benefit:

• Balance Sheet Stability: Real estate holdings provide asset-backed value and financial grounding.
• Margin Expansion: Consumer-centric ventures offer high growth potential when paired with ETST’s centralized management and branding strategies.

The Path Forward: Methodical Growth

The firm’s acquisition philosophy targets businesses with clear operational improvement and sustainable revenue. By prioritizing practical, methodical growth over speculative expansion, the company mitigates risk while positioning its subsidiaries for measurable impact.

Through centralized oversight and standardized governance, Earth Science Tech is building a resilient platform capable of navigating market cycles and capturing emerging opportunities in essential industries.

For more information, visit EarthScienceTech.com.

NOTE TO INVESTORS: The latest news and updates relating to ETST are available in the company’s newsroom at https://ibn.fm/ETST

• HeartBeam was included in a report published by Modern Healthcare that highlighted companies that achieved meaningful regulatory milestones or demonstrated forward momentum.
• HeartBeam’s technology is aligned with evolving regulatory and clinical priorities.
• In addition to being listed in the Modern Healthcare report, the company was also included in PatentVest’s “Total Cardiac Intelligence” report.

HeartBeam (NASDAQ: BEAT) was recently recognized among a select group of medical device companies featured in a January industry roundup highlighting recent U.S. Food and Drug Administration (“FDA”) clearances and approvals across the sector. The recognition underscores HeartBeam’s progress as it advances a novel approach to cardiac diagnostics through its HeartBeam System, a cable-free, high-fidelity ECG platform designed to capture the heart’s electrical signals from three distinct directions and synthesize them into a 12-lead ECG for arrhythmia assessment.

The company was included in a report published by Modern Healthcare and authored by Lauren Dubinsky. The report examined recent FDA activity across the medical device landscape, highlighting companies that achieved meaningful regulatory milestones or demonstrated forward momentum entering the new year. HeartBeam was included as part of this broader discussion of innovation and regulatory progress within the sector, reflecting growing attention on technologies aimed at improving access to clinical-grade data outside of traditional healthcare settings.

Being cited in the Modern Healthcare report places HeartBeam alongside other device developers whose products have either secured regulatory clearance or are progressing through the FDA process. The roundup focused on how recent approvals and regulatory decisions may shape the medical device market in the year ahead, particularly as healthcare systems continue to adopt technologies that support decentralization, remote monitoring and earlier intervention. HeartBeam’s mention reflects the relevance of its approach within these broader industry trends.

HeartBeam’s technology is aligned with evolving regulatory and clinical priorities. While many portable cardiac monitoring devices on the market provide limited, single-lead data intended primarily for wellness or screening purposes, HeartBeam is focused on delivering higher-fidelity signals. This emphasis on clinical-grade data helps explain why the company was included in a report centered on FDA activity and medical device innovation, rather than consumer health technology alone.

In addition to being listed in the Modern Healthcare report, the company was also included in PatentVest’s “Total Cardiac Intelligence” report. “HeartBeam recently reinforced its technology leadership with recognition as a Global IP and Technology Leader in Portable Cardiac Diagnostics, ranking second worldwide and trailing only GE Healthcare, in 12-lead ECG innovation among 243 companies evaluated,” the company noted in the announcement. The ranking reflects the strength of [HeartBeam’s] intellectual-property foundation, with 82 global patent publications across 15 patent families supporting its three-dimensional cardiac signal capture and 12-lead ECG synthesis architecture, underscoring the company’s growing influence in next-generation remote cardiac monitoring.

Beyond this recognition, the company continues to build toward its longer-term objective of bringing clinical-grade cardiac insights into more accessible environments. HeartBeam’s core platform, the HeartBeam System, is designed as the first cable-free, high-fidelity ECG system capable of capturing electrical signals from three distinct directions. This multidirectional approach enables a more comprehensive view of cardiac electrical activity than is possible with traditional handheld or wearable ECG devices that rely on a single signal pathway.

The HeartBeam System integrates electrodes into a compact handheld form factor, allowing patients to record ECG signals without adhesive patches, wires or external sensors. By simplifying the recording process while maintaining signal quality, the system is intended to support use in nonclinical settings, including at home or during symptomatic episodes that might otherwise go undocumented.

The inclusion of HeartBeam in the Modern Healthcare FDA roundup also highlights the growing importance of regulatory engagement for emerging medical device companies. Navigating the FDA process is a critical step in translating innovative technology into tools that can be adopted within mainstream healthcare. HeartBeam is working closely with regulators as it advances its platform, positioning the company to participate in a healthcare environment that increasingly values validated, high-quality data delivered beyond traditional care settings.

As the medical device sector enters the new year, attention is increasingly focused on technologies that can expand access to care, improve diagnostic efficiency and support earlier intervention. HeartBeam’s appearance in an industry-wide review of FDA activity reflects its alignment with these priorities. By developing a portable, cable-free ECG system designed to deliver clinically meaningful insights, the company is aiming to address persistent gaps in cardiac monitoring and arrhythmia assessment.

For more information, visit www.HeartBeam.com.

NOTE TO INVESTORS: The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT

Disseminated on behalf of  Powermax Minerals Inc. (CSE: PMAX) (OTCQB: PWMXF) and may include paid advertising.

• Powermax released Phase 2 stream sediment assay results from its Cameron Rare Earth Element Project in British Columbia, showing elevated light, heavy, and total rare earth oxides, across multiple drainage catchments.
• Results point to potential upstream bedrock sources and define priority areas for follow-up exploration.
• The company plans to integrate these findings with pending soil and rock sample data.
• Powermax is advancing a portfolio of REE assets in Canada and the U.S., including projects in Ontario and Wyoming.

Powermax Minerals (CSE: PMAX) (OTCQB: PWMXF), a Canadian mineral exploration company, recently reported new assay results from its Phase 2 stream sediment sampling program at the Cameron Rare Earth Element (“REE”) Project in British Columbia, outlining a series of anomalous rare earth values that management says will help refine exploration targets (https://ibn.fm/Ogebu).

The Toronto-based company said sampling across multiple drainage systems returned elevated light rare earth oxides (“LREO”), heavy rare earth oxides (“HREO”), and total rare earth oxides (“TREO”), reinforcing the effectiveness of stream sediment geochemistry as a tool for identifying REE mineralization. According to Powermax, Phase 2 assay results showed:

• LREO values ranging from 178.6 parts per million (“ppm”) to 47,980.5 ppm
• HREO values from 49.0 ppm to 9,537.3 ppm
• TREO values from 227.7 ppm to 57,517.8 ppm

Several drainage catchments displayed coherent multi-element anomalies, with enrichment in both light and heavy rare earths. The company also reported consistently high eTh/K ratios (greater than 10 in many samples), suggesting the presence of thorium-rich accessory minerals such as monazite or xenotime being transported downstream.

Management said these patterns indicate likely upstream bedrock sources and help define priority zones for follow-up geological mapping, soil sampling, and potential trenching or drill testing, subject to permitting.

“The Phase 2 stream sediment assay results further validate our systematic exploration approach at the Cameron Rare Earth Element Project,” CEO Paul Gorman said. “The broad range of elevated LREO, HREO, and TREO values across multiple drainage catchments highlights the extent and consistency of REE anomalies and confirms stream sediment geochemistry as an effective tool for defining priority target areas.” Gorman added that the company will integrate the new data with soil and rock sample results that are currently being processed.

Sampling for the Phase 2 program focused on active drainage systems. Sediments were sieved to less than 18 mesh and analyzed by AGAT Laboratories in Calgary, an ISO/IEC 17025:2017 accredited facility, using its 201-380 metals package. Powermax said quality control included the insertion of field duplicates. The Cameron REE Project is located in the Kamloops Mining Division of British Columbia and comprises three mineral claims totaling roughly 2,984 hectares. Powermax holds an option to acquire the property.

Beyond Cameron, Powermax is building a broader REE-focused portfolio. The company also holds options on the Atikokan REE Property and the Pinard REE Property in northern Ontario and owns a 100% interest in the Ogden Bear Lodge Project in Crook County, Wyoming.

Powermax positions itself as an early-stage exploration company aiming to identify and define economically viable rare earth deposits in Canada and the United States.

The company’s latest results arrive as rare earth elements continue to draw attention from investors and policymakers alike. Global demand for REEs is projected to rise sharply over the next decade, driven largely by electric vehicle production, wind power deployment, and other clean energy technologies. At the same time, China maintains a dominant role in both mining and processing, prompting efforts in North America to diversify supply chains.

In the United States, federal initiatives such as the Defense Production Act are being used to direct funding toward domestic and allied REE development, including grants and long-term purchase commitments. Canadian companies are eligible for parts of this funding, potentially providing additional support for exploration and downstream processing projects.

For Powermax, the Cameron results represent another technical data point as it works to advance its properties from early-stage exploration toward defined drill targets. While the company remains in the exploration phase, the growing dataset at Cameron is helping narrow the search for potential REE-bearing source rocks.

Exploration Target Cautionary Statement

The exploration targets discussed are conceptual, and there is currently not enough data to confirm a mineral resource. Further exploration may not yield successful results.

For more information, visit the company’s website at www.PowermaxMinerals.com.

NOTE TO INVESTORS: The latest news and updates relating to PWMXF are available in the company’s newsroom at https://ibn.fm/PWMXF

Disseminated on behalf of  ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF) and may include paid advertising.

• ESGold Corp., a development-stage mining company, just added 144 new mining claims in and around its Montauban project in Quebec
• The expansion follows the recent completion of an ANT-based 3D geological model, suggesting the potential for a mineralized corridor extending approximately 900 meters in depth and over two kilometers of strike
• The expansion allows ESGold to systematically and strategically evaluate the full extent of the Montauban mineral system, marking a critical inflection point for the company, with evaluation that is no longer constrained by historical evaluations

ESGold (CSE: ESAU) (OTCQB: ESAUF), a development-stage company committed to acquiring, exploring, and developing high-quality mineral properties worldwide, just added 144 new mining claims in and around its Montauban project, bringing the total to 417 mining claims. This milestone represents the largest contiguous mineral tenure held by a single company in the region. The move also ensures that the company is not constrained by historical boundaries that previously limited its operations (https://ibn.fm/bXFk9).

The expansion follows the recent completion of an ambient noise tomography (“ANT”)- based 3D geological model, which suggested the potential for a mineralized corridor extending to approximately 900 meters in depth and over 2 kilometers of strike, remaining open beyond the limits of the existing survey area at the property.

“The recently completed 3D geological model fundamentally changed our understanding of Montauban and underscored the importance of securing control over the broader geological system,” noted Gordon Robb, ESGold’s CEO. “While we remain hyper-focused on advancing Montauban toward near-term production of our tailings project, we are moving exploration forward in tandem, recognizing the opportunity to create value on two tracks simultaneously,” he added (https://ibn.fm/bXFk9).

This development positions ESGold to systematically and strategically evaluate the full extent of the Montauban mineral system, particularly given modern exploration that has advanced beyond the historically mined footprint. Going forward, the company expects to significantly expand its ANT survey to cover approximately 70 square kilometers. The goal with this would be to assess the scale and continuity of the broader mineralized corridor.

“The addition of nearly 76 square kilometers of strategically positioned ground around Montauban is aimed at providing the scale necessary to properly evaluate the potential extent of the mineralized corridor identified by the model and to ensure we are not constrained by the historical boundaries as we systematically assess what Montauban may ultimately become,” Robb noted (https://ibn.fm/bXFk9).

ESGold also plans to integrate ANT results with existing geological, geochemical, and structural datasets for the property, along with developing a targeted step-out diamond-drilling program focused on testing high-priority targets identified by the model and expanded geophysics.

The expanded land position marks a critical inflection point for ESGold. The company is positioned to systematically evaluate the full potential of the emerging mineral system while not being constrained by its historical land base and boundaries. It is an opportunity for ESGold to redefine the scale of its historic mining camp, all while advancing towards production.

For company information, visit the company’s website at www.ESGold.com.

NOTE TO INVESTORS: The latest news and updates relating to ESAUF are available in the company’s newsroom at https://ibn.fm/ESAUF